Literature DB >> 35347635

Gefapixant: First Approval.

Anthony Markham1.   

Abstract

Gefapixant (Lyfnua®; Merck & Co.) is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory chronic cough or unexplained chronic cough. Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or unexplained chronic cough. This article summarizes the milestones in the development of gefapixant leading to this first approval.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35347635     DOI： 10.1007/s40265-022-01700-8

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  8 in total

Review 1.  Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.

Authors:  David Muccino; Stuart Green
Journal:  Pulm Pharmacol Ther       Date:  2019-03-14       Impact factor: 3.410

2.  Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.

Authors:  David Richards; Joel R Gever; Anthony P Ford; Samuel J Fountain
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

3.  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

Authors:  Jaclyn A Smith; Michael M Kitt; Alyn H Morice; Surinder S Birring; Lorcan P McGarvey; Mandel R Sher; Yu-Ping Li; Wen-Chi Wu; Zhi Jin Xu; David R Muccino; Anthony P Ford
Journal:  Lancet Respir Med       Date:  2020-02-25       Impact factor: 30.700

4.  Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.

Authors:  Lorcan P McGarvey; Surinder S Birring; Alyn H Morice; Peter V Dicpinigaitis; Ian D Pavord; Jonathan Schelfhout; Allison Martin Nguyen; Qing Li; Anjela Tzontcheva; Beata Iskold; Stuart A Green; Carmen La Rosa; David R Muccino; Jaclyn A Smith
Journal:  Lancet       Date:  2022-03-05       Impact factor: 79.321

5.  Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.

Authors:  Jacqueline B McCrea; Azher Hussain; Bennett Ma; Graigory C Garrett; Raymond Evers; John E Laabs; S Aubrey Stoch; Marian Iwamoto
Journal:  Clin Pharmacol Drug Dev       Date:  2021-11-24

6.  Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.

Authors:  Fernando J Martinez; Amna Sadaf Afzal; Jaclyn A Smith; Anthony P Ford; Jerry Jing Li; Yuping Li; Michael M Kitt
Journal:  Pulm Ther       Date:  2021-06-21

7.  Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.

Authors:  Jesse C Nussbaum; Azher Hussain; Bennett Ma; K Chris Min; Qing Chen; Charles Tomek; Marian Iwamoto; S Aubrey Stoch
Journal:  Pharmacol Res Perspect       Date:  2022-02
  8 in total
  1 in total

Review 1.  Therapeutic potential for P2Y2 receptor antagonism.

Authors:  Kimberly J Jasmer; Kevin Muñoz Forti; Lucas T Woods; Seunghee Cha; Gary A Weisman
Journal:  Purinergic Signal       Date:  2022-10-11       Impact factor: 3.950
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.